CO7240392A2 - Método para identificar ligandos del receptor ahr que tienen actividad sebosupresora terapeútica, y los ligandos - Google Patents
Método para identificar ligandos del receptor ahr que tienen actividad sebosupresora terapeútica, y los ligandosInfo
- Publication number
- CO7240392A2 CO7240392A2 CO14273924A CO14273924A CO7240392A2 CO 7240392 A2 CO7240392 A2 CO 7240392A2 CO 14273924 A CO14273924 A CO 14273924A CO 14273924 A CO14273924 A CO 14273924A CO 7240392 A2 CO7240392 A2 CO 7240392A2
- Authority
- CO
- Colombia
- Prior art keywords
- ligands
- substance
- topical
- therapeutic
- ahr receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168121.7A EP2664919A1 (fr) | 2012-05-15 | 2012-05-15 | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7240392A2 true CO7240392A2 (es) | 2015-04-17 |
Family
ID=46801377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14273924A CO7240392A2 (es) | 2012-05-15 | 2014-12-12 | Método para identificar ligandos del receptor ahr que tienen actividad sebosupresora terapeútica, y los ligandos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9480674B2 (enExample) |
| EP (2) | EP2664919A1 (enExample) |
| JP (1) | JP6254580B2 (enExample) |
| KR (1) | KR20150022827A (enExample) |
| CN (1) | CN104471391B (enExample) |
| AU (1) | AU2013261093A1 (enExample) |
| BR (1) | BR112014028307A2 (enExample) |
| CA (1) | CA2873191A1 (enExample) |
| CO (1) | CO7240392A2 (enExample) |
| HK (1) | HK1205252A1 (enExample) |
| IL (1) | IL235449A (enExample) |
| IN (1) | IN2014DN10283A (enExample) |
| MX (1) | MX2014013925A (enExample) |
| NZ (1) | NZ702357A (enExample) |
| PH (1) | PH12014502548A1 (enExample) |
| RU (1) | RU2014150505A (enExample) |
| SG (1) | SG11201407405VA (enExample) |
| WO (1) | WO2013171696A1 (enExample) |
| ZA (1) | ZA201408826B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2082736A1 (fr) | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| CN110055320A (zh) * | 2012-03-17 | 2019-07-26 | 加州大学评议会 | 痤疮的快速诊断和个体化治疗 |
| EP2664919A1 (fr) | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
| WO2016022703A1 (en) * | 2014-08-06 | 2016-02-11 | Thesan Pharmaceuticals, Inc. | Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists |
| JP2016150916A (ja) * | 2015-02-17 | 2016-08-22 | 株式会社マンダム | 皮脂分泌抑制剤 |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| EP3448398A4 (en) | 2016-04-21 | 2019-12-18 | Naked Biome, Inc. | COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES |
| EP3522902B1 (en) | 2016-10-04 | 2025-09-03 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Probiotic bacteria producing an ahr agonist and their use in the treatment of metabolic syndrome and obesity |
| EP3920908A4 (en) | 2019-02-08 | 2022-10-05 | McMaster University | USE OF HYDROCARBON RECEPTOR ACTIVATORS IN THE TREATMENT OF GLUTEN-INDUCED GASTROINTESTINAL DISEASES |
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| CN114144078B (zh) * | 2019-07-23 | 2024-06-11 | 菲仕兰坎皮纳荷兰公司 | 包含乳脂肪和免疫球蛋白的营养组合物 |
| EP3875098A1 (en) | 2020-03-04 | 2021-09-08 | Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases |
| US20240417400A1 (en) * | 2021-10-14 | 2024-12-19 | Galileo Biosystems, Inc. | Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0614353A1 (en) * | 1991-11-25 | 1994-09-14 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
| WO1999047118A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions for regulating skin appearance |
| CA2408152A1 (en) * | 2000-05-05 | 2001-11-15 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| US6902881B2 (en) * | 2000-10-13 | 2005-06-07 | President And Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
| US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
| EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| FR2849597B1 (fr) * | 2003-01-08 | 2006-12-08 | Oreal | Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives |
| WO2006072203A1 (fr) * | 2005-01-05 | 2006-07-13 | Oliver Yoa-Pu Hu | Inhibiteur ou promoteur de l’uridinediphosphate-glucuronosyltransferase2b (ugt2b) |
| US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
| US20060210524A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin care composition |
| DE102005056890A1 (de) | 2005-11-28 | 2007-05-31 | Institut für Umweltmedizinische Forschung gGmbH | Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut |
| KR100798252B1 (ko) * | 2006-01-18 | 2008-01-24 | 주식회사 엘지생활건강 | ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물 |
| DE102006011747A1 (de) * | 2006-03-13 | 2007-09-27 | Symrise Gmbh & Co. Kg | Dermatologische und/oder kosmetische Zubereitungen |
| EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
| EP2035430A1 (en) | 2006-05-03 | 2009-03-18 | Symrise GmbH & Co. KG | 6h-benzofuro[3,2-c][1]benzopyran and [2]benzopyrano [4,3-b][1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage |
| US20080317684A1 (en) * | 2006-09-06 | 2008-12-25 | Isw Group, Inc. | Topical Compositions |
| EP2082736A1 (fr) | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| KR20110139397A (ko) * | 2010-06-23 | 2011-12-29 | 건국대학교 산학협력단 | 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물 |
| CN101953838A (zh) * | 2010-08-13 | 2011-01-26 | 李岱 | 吴茱萸次碱用于治疗银屑病的应用 |
| EP2664919A1 (fr) | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
-
2012
- 2012-05-15 EP EP12168121.7A patent/EP2664919A1/fr not_active Withdrawn
-
2013
- 2013-05-15 AU AU2013261093A patent/AU2013261093A1/en not_active Abandoned
- 2013-05-15 RU RU2014150505A patent/RU2014150505A/ru not_active Application Discontinuation
- 2013-05-15 WO PCT/IB2013/053979 patent/WO2013171696A1/en not_active Ceased
- 2013-05-15 CA CA2873191A patent/CA2873191A1/en not_active Abandoned
- 2013-05-15 NZ NZ702357A patent/NZ702357A/en not_active IP Right Cessation
- 2013-05-15 SG SG11201407405VA patent/SG11201407405VA/en unknown
- 2013-05-15 CN CN201380025088.6A patent/CN104471391B/zh not_active Expired - Fee Related
- 2013-05-15 JP JP2015512185A patent/JP6254580B2/ja not_active Expired - Fee Related
- 2013-05-15 HK HK15105467.6A patent/HK1205252A1/xx unknown
- 2013-05-15 EP EP13734844.7A patent/EP2850429A1/en not_active Withdrawn
- 2013-05-15 BR BR112014028307A patent/BR112014028307A2/pt not_active IP Right Cessation
- 2013-05-15 MX MX2014013925A patent/MX2014013925A/es unknown
- 2013-05-15 IN IN10283DEN2014 patent/IN2014DN10283A/en unknown
- 2013-05-15 KR KR20147035211A patent/KR20150022827A/ko not_active Withdrawn
-
2014
- 2014-11-02 IL IL235449A patent/IL235449A/en not_active IP Right Cessation
- 2014-11-07 US US14/536,507 patent/US9480674B2/en not_active Expired - Fee Related
- 2014-11-14 PH PH12014502548A patent/PH12014502548A1/en unknown
- 2014-12-02 ZA ZA2014/08826A patent/ZA201408826B/en unknown
- 2014-12-12 CO CO14273924A patent/CO7240392A2/es unknown
-
2016
- 2016-10-26 US US15/334,987 patent/US20170042856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150057343A1 (en) | 2015-02-26 |
| ZA201408826B (en) | 2016-09-28 |
| AU2013261093A1 (en) | 2014-12-18 |
| CN104471391A (zh) | 2015-03-25 |
| KR20150022827A (ko) | 2015-03-04 |
| JP6254580B2 (ja) | 2017-12-27 |
| IN2014DN10283A (enExample) | 2015-08-07 |
| WO2013171696A1 (en) | 2013-11-21 |
| EP2850429A1 (en) | 2015-03-25 |
| PH12014502548A1 (en) | 2015-01-21 |
| BR112014028307A2 (pt) | 2017-07-18 |
| NZ702357A (en) | 2016-10-28 |
| EP2664919A1 (fr) | 2013-11-20 |
| MX2014013925A (es) | 2015-05-11 |
| CN104471391B (zh) | 2016-12-07 |
| IL235449A (en) | 2017-07-31 |
| JP2015523553A (ja) | 2015-08-13 |
| SG11201407405VA (en) | 2014-12-30 |
| CA2873191A1 (en) | 2013-11-21 |
| US20170042856A1 (en) | 2017-02-16 |
| RU2014150505A (ru) | 2016-07-10 |
| HK1205252A1 (en) | 2015-12-11 |
| US9480674B2 (en) | 2016-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502548A1 (en) | Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands | |
| CO2020008972A2 (es) | Nanopartícula de lípido que contiene ácido nucleico y uso de la misma | |
| CY1123106T1 (el) | Αγωγη ανοσοσχετιζομενων και φλεγμονωδων νοσων | |
| NI201300041A (es) | Antagonistas de mdm2 de espiro-oxindol | |
| MX2021001837A (es) | Constructos del receptor de celulas t y usos de los mismos. | |
| MX2019004181A (es) | Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano. | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| MX2023000731A (es) | Composiciones utiles para enzimas de internalizacion. | |
| MX2019007981A (es) | Terapeutica de proteinas para el tratamiento de celulas senescentes. | |
| CL2017001296A1 (es) | Anticuerpos contra cd73 y sus usos | |
| MX2016006625A (es) | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. | |
| EP2917180A4 (en) | GPR40 RECEPTOR AGONIST, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE SUBSTANCE | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| MX2016010998A (es) | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. | |
| CL2016001940A1 (es) | Composición farmacéutica que contiene un compuesto derivado de imidazo[1,5-a]indol, [1,2,4]triazolo[3,4-a]isoindol, [1,2,3]triazolo[5,1-a]isoindol ó 1,4-dihidroindeno[1,2-c] sustituidos y un segundo agente terapéutico; y su uso tratar la inmunosupresión mediada por indoleamina 2,3-dioxigenasa (ido), estimular la proliferación de células t, inhibir la degradación de triptófano en células que expresa ido, para tratar una enfermedad asociada con ido como una infección o cáncer (divisional de solicitud n° 2649-2015). | |
| UY35448A (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 | |
| DOP2015000108A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| MX362442B (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1alfa). | |
| EP2832851A4 (en) | IMMORTALIZED STEM CELLS AND MEDICAL COMPOSITION AND MEDICAMENT WITH A PRODUCT THEREOF AS AN ACTIVE SUBSTANCE | |
| AR105592A1 (es) | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS | |
| AR087471A1 (es) | Metodos de tratamiento de enfermedades degenerativas de la retina | |
| UY35852A (es) | ?aparato de soporte para aves y procedimiento asociado?. | |
| CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas |